Journal article · 2026 · Open access

Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

Jeffrey L. Cummings, Alireza Atri, Mary Sano, Henrik Zetterberg, Philip Scheltens, Filip K Knop, Peter Johannsen, Christian Ahmad Wichmann, Rikke Mortensen Abschneider, Teresa León, Howard Feldman

The Lancet, 407(10544), 2167–2179 · Published 19 March 2026 · DOI 10.1016/s0140-6736(26)00459-9

Open full textCite this paper

In brief

“Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials” is a 2026 journal article by Jeffrey L. Cummings and 10 co-authors, published in The Lancet. OpenAlex counts 136 citations as of 16 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet.

Citations
136
Most cited in
2026 (136)
Field-weighted impact
187.62
References
24
Authors
11

Abstract

BACKGROUND: Evidence, including animal, clinical, and real-world studies in individuals with type 2 diabetes and/or obesity, suggests reduced risk of dementia and Alzheimer's disease after GLP-1 receptor agonist exposure. The evoke and evoke+ trials aimed to investigate the efficacy and safety of oral semaglutide in individuals with early Alzheimer's disease. METHODS: evoke and evoke+ were multicentre, randomised, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 countries. The trials assessed the efficacy and safety of oral semaglutide up to 14 mg once daily in participants with amyloid-confirmed Alzheimer's disease, aged 55-85 years, with mild cognitive impairment or mild dementia due to Alzheimer's disease. In evoke+, participants with significant small vessel pathology were included. Participants were randomly assigned (1:1) to once-daily semaglutide 14 mg (flexible dose) or placebo for up to 156 weeks. The primary endpoint was change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) score from baseline to week 104, assessed in all randomised participants. Safety was assessed in all randomised participants and reported for those receiving at least one dose of study drug. These trials were registered at ClinicalTrials.gov (NCT04777396 and NCT04777409); both trials have been discontinued due to negative clinical outcome. FINDINGS: Between May 18, 2021, and Sept 8, 2023, 9981 participants were screened, of whom 3808 were randomly assigned; 1855 in evoke (semaglutide, n=928; placebo, n=927) and 1953 in evoke+ (semaglutide, n=976; placebo, n=977). Mean age was 72·2 years (SD 7·1), and mean CDR-SB score was 3·7 (SD 1·6) at baseline. In evoke+, 54 (2·8%) participants had small vessel pathology. In evoke and evoke+, mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+). Treatment-emergent adverse events were reported in 1729 (91·2%) of 1896 participants receiving semaglutide versus 1613 (84·8%) of 1902 receiving placebo. There were five fatalities considered treatment-related by the investigators (one in the semaglutide group and four in the placebo group). INTERPRETATION: Oral semaglutide was not efficacious in slowing clinical progression in participants with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's disease is consistent with studies in other indications. FUNDING: Novo Nordisk.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., León, T., & Feldman, H. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet, 407(10544), 2167–2179. https://doi.org/10.1016/s0140-6736(26)00459-9

MLA 9

Cummings, Jeffrey L., et al. “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.” The Lancet, vol. 407, no. 10544, 2026, pp. 2167–2179. https://doi.org/10.1016/s0140-6736(26)00459-9.

Chicago

Cummings, Jeffrey L., Alireza Atri, Mary Sano, Henrik Zetterberg, Philip Scheltens, Filip K Knop, Peter Johannsen, et al. 2026. “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.” The Lancet 407 (10544): 2167–2179. https://doi.org/10.1016/s0140-6736(26)00459-9.

Harvard

Cummings, J. L. et al. (2026) ‘Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials’, The Lancet, 407(10544), pp. 2167–2179. doi:10.1016/s0140-6736(26)00459-9.

IEEE

J. L. Cummings et al., “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials,” The Lancet, vol. 407, no. 10544, pp. 2167–2179, 2026, doi: 10.1016/s0140-6736(26)00459-9.

BibTeX

@article{cummings2026efficacy,
  title     = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials}},
  author    = {Cummings, Jeffrey L. and Atri, Alireza and Sano, Mary and Zetterberg, Henrik and Scheltens, Philip and Knop, Filip K and Johannsen, Peter and Wichmann, Christian Ahmad and Abschneider, Rikke Mortensen and León, Teresa and Feldman, Howard},
  journal   = {The Lancet},
  year      = {2026},
  volume    = {407},
  number    = {10544},
  pages     = {2167--2179},
  doi       = {10.1016/s0140-6736(26)00459-9},
  url       = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • semaglutide
  • Alzheimer's disease
  • GLP-1 receptor agonists
  • oral semaglutide
  • early Alzheimer's disease
  • mild cognitive impairment
  • mild dementia
  • CDR-SB

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., León, T., & Feldman, H. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet, 407(10544), 2167–2179. https://doi.org/10.1016/s0140-6736(26)00459-9

How many times has this paper been cited?

136 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet: sign in and open the full text from this page.

Who wrote this paper?

Jeffrey L. Cummings, Alireza Atri, Mary Sano, Henrik Zetterberg, Philip Scheltens, Filip K Knop, Peter Johannsen, Christian Ahmad Wichmann, Rikke Mortensen Abschneider, Teresa León, Howard Feldman.

What is the DOI of this paper?

10.1016/s0140-6736(26)00459-9, permanently at https://doi.org/10.1016/s0140-6736(26)00459-9. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.